The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.